John Mendelsohn - Merrimack Pharmaceuticals Insider

MACK -- USA Stock  

USD 5.16  0.11  2.18%

  Director
Dr. John Mendelsohn, M.D. is an Independent Director of the Company. He has served as a member of our board of directors since June 2012. Dr. Mendelsohn has served as the CoDirector of the Khalifa Institute for Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center since September 2011. Dr. Mendelsohn also served as President of the MD Anderson Cancer Center from 1996 to August 2011. Prior to joining the MD Anderson Cancer Center, Dr. Mendelsohn was founding director of the cancer center at the University of California San Diego and served as Chairman of Medicine at Memorial SloanKettering Cancer Center from 1985 to 1996. Dr. Mendelsohn also currently serves as the L.E. and Virginia Simmons Senior Fellow in Health and Technology Policy at the James A. Baker, III Institute for Public Policy. Dr. Mendelsohn is recognized for his research on the binding of growth factors to cell surface receptors and how they regulate cell functions, which led to the discovery, development and eventual commercialization of the cancer therapy cetuximab
Age: 78  Director Since 2012      
617-441-1000  http://www.merrimack.com
Mendelsohn holds an M.D. from Harvard Medical School and a B.S. from Harvard College.

John Mendelsohn Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (29.17) % which means that it has lost $29.17 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (63.21) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

DIRECTOR Since

Robert HoffmanDelMar Pharmaceuticals
2018
John PottsNantKwest
2014
Laura BregeDynavax Technologies Corporatio
2015
John BellDelMar Pharmaceuticals
2013
Fred MiddletonEndocyte
2001
Ann HanhamEndocyte
2004
Robert TothDelMar Pharmaceuticals
2013
Armando AnidoAuris Medical Holding AG
2016
Kevin BuchiDicerna Pharmaceuticals
2018
Robert RosenNantKwest
N/A
Lesley RussellEndocyte
2017
Peggy PhillipsDynavax Technologies Corporatio
2006
Dennis CarsonDynavax Technologies Corporatio
1997
Nancy WysenskiDova Pharmaceuticals
2018
William GarnerDelMar Pharmaceuticals
2013
John ThomasNantKwest
2014
Steven GoldmanDova Pharmaceuticals
2017
Calvin RobertsAuris Medical Holding AG
2015
Alfred NovakDova Pharmaceuticals
2017
Napoleone FerraraDelMar Pharmaceuticals
2018
Peter KolchinskyDicerna Pharmaceuticals
2013

Entity Summary

Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Merrimack Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 72 people.Merrimack Pharmaceuticals (MACK) is traded on BATS Exchange in USA. It is located in Massachusetts U.S.A and employs 72 people. Merrimack Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Merrimack Pharmaceuticals Leadership Team

Robert Mulroy, CEO and President Executive Director and Member of Executive Committee
George Demetri, Director
Gary Crocker, Independent Chairman of the Board
Vivian Lee, Director
James Quigley, Director
Birgit Schoeberl, Head of Discovery
Richard Peters, President CEO, Principal Financial Officer, Director
Ulrik Nielsen, Chief Scientific Officer and Sr. VP of Research
John Mendelsohn, Director
John Green, Chief Accounting Officer, Controller
Ellen Forest, Head of Human Resources
Yasir AlWakeel, CFO and Head - Corporate Development
Edward Stewart, Sr. VP of Bus. Devel. and President of Merrimack Healthcare Solutions
Jean Franchi, CFO,Principal Financial Officer, Principal Accounting Officer, Treasurer
William Sullivan, Head of Fin. and Accounting and Treasurer
William Mcclements, Head of Corporate Operations
John Dineen, Director
Russell Ray, Director
Peter Laivins, Head of Devel.
Michael Porter, Independent Director
Geoffrey Grande, IR Contact Officer
Sergio Santillana, Chief Medical Officer

Stock Performance Indicators

Current Sentiment - MACK

Merrimack Pharmaceuticals Investor Sentiment

Most of Macroaxis users are now bullish on Merrimack Pharmaceuticals. What is your trading attitude regarding investing in Merrimack Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Search macroaxis.com